Fundraising FoxAutifony Therapeutics
Stevenage, GB · 4 known investors
Find your way into Autifony Therapeutics
Sign up to see every warm intro you have to Autifony Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Autifony Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Autifony Therapeutics is a privately funded biopharmaceutical company developing treatments for neurological conditions including Fragile X Syndrome and orphan epilepsy syndromes.
Founders & leadership
Investors · 4
Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M
How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us
SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20M
How we know: SV Health Investors's portfolio page · Not right? Tell us
Innovate UKreportedLondon
How we know: biospace.com · Not right? Tell us
Companies House · registry record
View on Companies House ↗- Registered name
- AUTIFONY THERAPEUTICS LIMITED
- Company number
- 07543962
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 25 Feb 2011
- Registered office
- Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2FX
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Previous names
- NEWINCCO 1091 LIMITED (2011–2011)
- Accounts
- last made up to 30 Sept 2025 · next due 30 Jun 2027
- Confirmation statement
- last made up to 25 Feb 2026 · next due 11 Mar 2027
Current officers · 6
- Hannah Louise Selin — secretary, appointed 7 May 2025
- Rana Al-Hallaq — director, appointed 15 Apr 2019
- John Edward Berriman — director, appointed 23 May 2011
- Catherine Elizabeth Bingham — director, appointed 19 Aug 2011
- Charles Henry Large — director, appointed 23 May 2011
- Ip2ipo Services Limited — corporate director, appointed 12 Mar 2018
Source: Companies House public register · retrieved 4 Oct 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Autifony Therapeutics do?
- Autifony Therapeutics is a privately funded biopharmaceutical company developing treatments for neurological conditions including Fragile X Syndrome and orphan epilepsy syndromes.
- Who founded Autifony Therapeutics?
- Autifony Therapeutics was founded by Charles H. Large.
- Who are Autifony Therapeutics's investors?
- Autifony Therapeutics's investors include Pfizer Venture Investments, SV Health Investors, Dementia Discovery Fund, Innovate UK.
- Where is Autifony Therapeutics headquartered?
- Autifony Therapeutics is headquartered in Stevenage, GB.